{
    "clinical_study": {
        "@rank": "50317", 
        "acronym": "AMOR", 
        "arm_group": {
            "arm_group_label": "Aflibercept", 
            "arm_group_type": "Experimental", 
            "description": "Aflibercept in combination with XELOX (oxaliplatin and capecitabine), administered every 3 weeks up to 6 cycles as induction therapy, followed by single-agent aflibercept, as maintenance, up to disease progression, unacceptable toxicity or patient's refusal of further study treatment."
        }, 
        "brief_summary": {
            "textblock": "Primary Objectives:\n\n      Study Part 1: To determine the recommended dose for the aflibercept, oxaliplatin and\n      capecitabine (XELOX) combination to be used in the Part 2 of the study.\n\n      Study Part 2: To assess the percentage of patients without progression of the disease at 6\n      months after the start of maintenance therapy with aflibercept single-agent, following the\n      first-line induction therapy with XELOX and aflibercept combination in patients with\n      previously untreated metastatic colorectal cancer.\n\n      Secondary Objective:\n\n      Study Part 2: Include the evaluation of progression free survival, overall survival,\n      response to treatment,  the overall safety (during induction and maintenance therapy) and\n      the assessment of aflibercept pharmacodynamics and biomarkers parameters."
        }, 
        "brief_title": "Study of Aflibercept as Maintenance Therapy Following Induction With Aflibercept in Combination With XELOX, as First-Line Treatment for Metastatic Colorectal Cancer Patient", 
        "completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Colorectal Cancer Metastatic", 
        "condition_browse": {
            "mesh_term": [
                "Colorectal Neoplasms", 
                "Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "The duration of the study for each patient includes a period for screening of up to 3 weeks,\n      study drug administrations every 3 weeks up to disease progression, unacceptable toxicity or\n      patient's refusal of further study treatment, followed by a minimum of 30-day follow-up\n      after the last study treatment administration.\n\n      After study treatment discontinuation each patient will be followed-up until death,\n      patient's refusal or end of study (whichever comes first).\n\n      This trial is being conducted in Europe, where the INN designation for the study molecule is\n      \"aflibercept\" and this term is therefore used throughout the synopsis. In the US, the US\n      proper name is \"ziv-aflibercept\"."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n          -  Histologically or cytologically-proven adenocarcinoma of the colon or rectum.\n\n          -  Metastatic disease not amenable to potentially curative treatment (i.e.\n             unresectable).\n\n          -  Measurable lesion as assessed by RECIST criteria.\n\n          -  No prior systemic anti-cancer treatment for metastatic disease.\n\n          -  No prior adjuvant treatment after resection of distant metastases.\n\n          -  No prior treatment with angiogenesis inhibitors.\n\n        Exclusion criteria:\n\n          -  Age <18 years.\n\n          -  Eastern Cooperative Oncology Group Performance status >/= 2.\n\n          -  Less than 4 weeks from prior radiotherapy or prior surgery (or until the surgical\n             wound is fully healed).\n\n          -  Treatment with any other investigational product within the prior 28 days.\n\n          -  Other prior neoplasm.\n\n          -  History of brain metastases, active seizure disorder, uncontrolled spinal cord\n             compression, or carcinomatous meningitis, or new evidence of brain or leptomeningeal\n             disease.\n\n          -  Any of the following within the prior 6 months: myocardial infarction,\n             severe/unstable angina pectoris, coronary/peripheral artery bypass graft, severe\n             congestive heart failure, stroke or transient ischemic attack.\n\n          -  Any of the following within the prior 3 months: moderate/severe gastrointestinal\n             bleeding/hemorrhage, treatment resistant peptic ulcer disease, erosive oesophagitis\n             or gastritis, infectious or inflammatory bowel disease, diverticulitis, pulmonary\n             embolism or other uncontrolled thromboembolic event.\n\n          -  Deep vein thrombosis within the prior 4 weeks.\n\n          -  Any severe acute or chronic medical condition, which could impair the ability of the\n             patient to participate in the study.\n\n          -  Inadequate bone marrow, liver and renal function: neutrophils < 1.5x10^9/L, platelets\n             < 100x10^9/L, hemoglobin < 9.0 g/dL, total bilirubin >1.5 x upper normal limit (ULN),\n             transaminases >3 x ULN (unless liver metastasis are present), alkaline phosphatase >3\n             x ULN (unless liver metastasis are present), serum creatinine > 1.5 x ULN.\n\n          -  Patients on anticoagulant therapy with warfarin.\n\n          -  Symptomatic peripheral sensory neuropathy.\n\n          -  Inability to take oral medications.\n\n          -  Prior history of chronic enteropathy, inflammatory enteropathy, chronic diarrhea,\n             malabsorption syndrome, unresolved bowel obstruction/sub-obstruction, surgery more\n             extensive than hemicolectomy, extensive small intestine resection with chronic\n             diarrhea.\n\n          -  Known dihydropyrimidine dehydrogenase deficiency.\n\n          -  known history of hypersensitivity to aflibercept.\n\n          -  Any contraindication to administer oxaliplatin or capecitabine as per package insert\n             of each drug.\n\n          -  Urine protein-creatinine ratio (UPCR) >1 on morning spot urinalysis or proteinuria >\n             500 mg/24-h.\n\n          -  Uncontrolled hypertension within the prior 3 months.\n\n          -  Evidence of clinically significant bleeding predisposition or underlying\n             coagulopathy, non-healing wound.\n\n          -  Pregnant or breast-feeding women.\n\n          -  Patients with reproductive potential who do not agree to use an accepted effective\n             method of contraception.\n\n        The above information is not intended to contain all considerations relevant to a\n        patient's potential participation in a clinical trial."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "90", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 13, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01955629", 
            "org_study_id": "AFLIBC06561", 
            "secondary_id": [
                "2013-000858-22", 
                "U1111-1143-3015"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "Aflibercept", 
                "description": "Pharmaceutical form:Concentrate for solution for infusion Route of administration: intravenous", 
                "intervention_name": "AFLIBERCEPT AVE0005", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Aflibercept", 
                "description": "Pharmaceutical form:Concentrate for solution for infusion Route of administration: intravenous", 
                "intervention_name": "OXALIPLATIN", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Aflibercept", 
                "description": "Pharmaceutical form:Tablets Route of administration: oral", 
                "intervention_name": "CAPECITABINE", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Oxaliplatin", 
                "Capecitabine"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "June 4, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Genova", 
                        "country": "Italy", 
                        "zip": "16132"
                    }, 
                    "name": "Investigational Site Number 380-001"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Milano", 
                        "country": "Italy"
                    }, 
                    "name": "Investigational Site Number 380-002"
                }
            }
        ], 
        "location_countries": {
            "country": "Italy"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Single-Arm, Open Label Study of Aflibercept as Maintenance Therapy Following Induction With Aflibercept in Combination With XELOX, as First-Line Treatment for Metastatic Colorectal Cancer Patient", 
        "overall_official": {
            "affiliation": "Sanofi", 
            "last_name": "Clinical Sciences & Operations", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Italy: Ethics Committee", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Study Part 1: treatment related Dose Limiting Toxicity(ies) (DLTs) observed at first cycle", 
                "safety_issue": "Yes", 
                "time_frame": "At 3 weeks (completion of first cycle) for patients included in dose-escalation study Part 1"
            }, 
            {
                "measure": "Study Part 2: proportion of patients alive without progression at 6 months after the start of the maintenance therapy", 
                "safety_issue": "No", 
                "time_frame": "6 months after the start of the maintenance therapy"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01955629"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Study Part 1: number of patients reporting adverse events or laboratory abnormalities per each dose level tested", 
                "safety_issue": "Yes", 
                "time_frame": "At each cycle, at 30 days after the last treatment, up to an estimation of 34 weeks"
            }, 
            {
                "measure": "Study Part 1: Tumor response category: Complete Response (CR), Partial Response (PR), No Change (NC) or Progressive Disease (PD)", 
                "safety_issue": "No", 
                "time_frame": "Every 9 weeks from treatment start up to the first documentation of disease progression"
            }, 
            {
                "measure": "Study Part 2: Progression free survival", 
                "safety_issue": "No", 
                "time_frame": "Study period, approximately 2.5 years"
            }, 
            {
                "measure": "Study Part 2: Overall survival", 
                "safety_issue": "No", 
                "time_frame": "Study period, approximately 2.5 years"
            }, 
            {
                "measure": "Study Part 2: Proportion of patients reaching a total metastases resection (if applicable)", 
                "safety_issue": "No", 
                "time_frame": "Up to 12 months after the end of study enrollment"
            }, 
            {
                "measure": "Study Part 2:  Proportion of patients with complete or partial response as defined in RECIST 1.1 criteria", 
                "safety_issue": "No", 
                "time_frame": "Up to 12 months after the end of study enrollment"
            }, 
            {
                "measure": "Study Part 2: Number of patients reporting adverse events or laboratory abnormalities as per NCI-CTCAE 4.03 criteria", 
                "safety_issue": "Yes", 
                "time_frame": "Every cycle up to 30 days after the last treatment administration, study period"
            }, 
            {
                "measure": "Study Part 2: Aflibercept pharmacodynamic parameters evaluation", 
                "safety_issue": "No", 
                "time_frame": "Up to an average of 34 weeks"
            }, 
            {
                "measure": "Study Part 2: Aflibercept biomarkers evaluation", 
                "safety_issue": "No", 
                "time_frame": "Up to an average of 34 weeks"
            }
        ], 
        "source": "Sanofi", 
        "sponsors": {
            "collaborator": {
                "agency": "Regeneron Pharmaceuticals", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Sanofi", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2014"
    }
}